AbbVie's (ABBV.US) CD3, CD20 bispecific antibody eculizumab has been submitted for approval in China.

AInvestTuesday, Nov 5, 2024 7:20 pm ET

1min read

On November 6, the CDE's website showed that ABBV's (ABBV.US) CD3/CD20 bispecific antibody epcoritamab (Epkinly in the US) was under review for market approval in China.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.